What is Surrozen?
Surrozen is a clinical-stage biotechnology firm dedicated to the discovery and development of drug candidates that selectively modulate the Wnt pathway. By leveraging tissue-specific antibodies, the company aims to engage the body's innate biological repair mechanisms. This innovative approach holds transformative potential for treating diseases characterized by tissue damage or degeneration, including hepatitis, lung and airway diseases, and various sensory impairments. Surrozen's market position is defined by its unique ability to translate complex biological insights into targeted therapeutic interventions, effectively bridging the gap between fundamental research and clinical application.
How much funding has Surrozen raised?
Surrozen has raised a total of $308M across 4 funding rounds:
Series A
$33M
Series B
$50M
Series C
$50M
Share Placement
$175M
Series A (2017): $33M with participation from The Column Group
Series B (2019): $50M led by The Column Group
Series C (2020): $50M supported by The Column Group, Horizons Ventures, and Hartford Healthcare Trust
Share Placement (2025): $175M, investors not publicly disclosed
Key Investors in Surrozen
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that nurtures early-stage technology platforms.
Horizons Ventures
Horizons Ventures is a venture capital firm with over 20 years of experience helping entrepreneurs transform startup ventures into successful, scalable companies through active involvement and equity financing.
Hartford Healthcare Trust
An institutional investor providing strategic capital to support the advancement of healthcare innovation and medical research initiatives.
What's next for Surrozen?
With the recent influx of capital, Surrozen is well-positioned to advance its lead candidates through critical clinical milestones. The strategic focus will likely shift toward expanding its therapeutic footprint and optimizing its antibody platform for broader clinical utility. As the company matures, the emphasis will remain on rigorous data generation and potential collaborative partnerships to navigate the complex regulatory landscape of the biotech industry. Investors and stakeholders will be closely monitoring the progression of its pipeline as it seeks to redefine the standard of care for patients suffering from chronic, tissue-degenerative conditions.
See full Surrozen company page
